Press Releases

Expands portfolio with three new kitted transplant products launching in 2019 Delivers new insights into the clinical Transplantome by incorporating HLA plus additional genes contributing to successful transplant outcomes Enables global access for laboratories to assess organ health by measuring

BRISBANE, Calif. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,

Launches HeartCare registry to increase patient access to comprehensive surveillance solution of AlloMap and AlloSure Heart BRISBANE, Calif. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and

BRISBANE, Calif. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,

AlloSure launch momentum drives 48% revenue growth BRISBANE, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for

BRISBANE, Calif. , July 16, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release

Amy Abernethy adds clinical expertise and patient data insights to the CareDx Board BRISBANE, Calif. , June 28, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value

BRISBANE, Calif. , June 19, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that it is set to join

The progressive CareDx Living Donor Employee Recovery Policy announced at ATC BRISBANE, Calif. , June 05, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value

CareDx will have a strong presence at ATC, all major US transplant centers will be in attendance BRISBANE, Calif. , June 01, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated,